NASDAQ · NVNOW
enVVeno Medical Corporation
Healthcare · Medical - Devices
$0.01
Down-$0.00 (-32.98%)
Updated Aug 15, 2026, 6:44 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 73.65M
- P/E ratio
- -0.33
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 24.25K
- Avg. volume
- 8.35K
Price performance
NVNOW price history
1M range · 0 trading sessions · Daily adjusted prices
NVNOW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NVNOW news
The latest Smart Investors Daily articles mentioning NVNOW.
Stock researchCompany · Overview
NVNOW research
Overview
Company profile and research snapshot.
Company profile
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
